Second French Trial Tragedy Verdict: No Danger Signs In Lower Dose Triallists
Executive Summary
A second committee has given its opinion on the Phase I trial tragedy in France earlier this year in which one volunteer died and four others were hospitalized after suffering neurological damage. The panel found that while some neurological signals were seen in about half of the other 80-odd volunteers, these were in line with what would be expected in a first-in-human clinical trial and differed from the lesions seen in the volunteers who were hospitalized.
You may also be interested in...
French Say Phase I Inquiry Findings To Feed Into Review Of EU First-In-Man Guidelines
The French health minister, Marisol Touraine, says that she intends to send the dossiers on the 90 volunteers who took part in the disastrous Phase I FAAH inhibitor study in Rennes to the working groups that have been set up at EU level to look into possible changes to the EU guidelines on first-in-man studies1,2.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.